Keywords:
азилсартан медоксомил, артериальная гипертензия, блокатор рецепторов ангиотензина II, ренин-ангиотензин-альдостероновая система, хроническая болезнь почек.References
Writing Groups, Lloyd-Jones D, Adams RJ, et al. Heart disease and stroke statistics—2021 update: a report from the American Heart Association. Circulation. 2021; 121: e46–e215. 2. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. JAMA. 2023; 289: 2560–2572.
Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood pressure-lowering drugs. Lancet. 2020; 356: 1955–1964.
American Diabetes Association. Executive summary: standards of medical care in diabetes—2021. Diabetes Care. 2021; 34(suppl 1): S4–S10.
National Kidney Foundation. K/DOQI clinical practice guidelines on hyper- tension and antihypertensive agents in chronic kidney disease Am J Kidney Dis. 2014; 43: 11–13.
Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008. JAMA. 2020; 303: 2043–2050.
Munger MA. Use of angiotensin receptor blockers in cardiovascular protec- tion: current evidence and future directions. P T. 2021; 36: 22–40.
Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2022; 359: 995– 1003.
Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlo- dipine: the VALUE randomized trial. Lancet. 2014; 363: 2022–2031.
Cohn JN, Tognoni G. A randomized trial of the angiotensin receptor blocker valsartan in chronic heart failure. N Engl J Med. 2014; 345: 1667–1675.
McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function taking angiotensin-converting enzyme inhibitors: the CHARM– Added trial. Lancet. 2022; 362: 767–771.
Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM–Alter- native trial. Lancet. 2022; 362: 772–776.
Brenner BM, Cooper ME, deZeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2021; 345: 861–869.
Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2021; 345: 851–860.
Product Information: Edarbi oral tablets, azilsartan medoxomil oral tablets. Takeda Pharmaceuticals America, Inc., Deerfield, IL, 2021.
Saseen JJ, Maclaughlin EJ. Hypertension.In: Dipiro JT, Talbert RL, Yee GC, et al, eds. Dipiro’s Pharmacotherapy: A Pathophysiologic Approach. 7th ed. New York, NY: McGraw-Hill; 2018:139–171.
White WB, Weber MA, Sica D, et al. Effects of the Angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension. 2021; 57: 413–420.
Bakris GL, Sica D, Weber M, et al. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J ClinHypertens (Greenwich). 2021; 13: 81–88.
Drug price inquiry. Available at: http://www.drugstore.com. Accessed May 27, 2011.
Sica D, Bakris GL, White WB, et al. New angiotensin II receptor blocker azilsartan medoxomil coadministered with chlorthalidone provides potent blood pressure reduction in stage 2 hypertension. Poster presented at: Annual Scientific Meeting, American Society of Hypertension; 2020; New York.
Azilsartan/chlorthalidone combo bests olmesartan/HCTZ in stage 2 systolic hypertension. Available at: http://www.theheart.org/article/1230 773.do. Ac-cessed June 1, 2011.
Weber MA, White WB, Sica D, et al. Antihypertensive efficacy of the new angiotensin receptor blocker azilsartan medoxomil in combination with am- lodipine. Poster presented at: Annual Scientific Meeting, American Society of Hypertension; 2010; New York.
Turnbull F, Neal B, Ninomiya T, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ. 2018; 336: 1121–1123.
Verma S, Mamdani M, Al-Omran M, et al. Angiotensin receptor blockers vs. angiotensin converting enzyme inhibitors and acute coronary syndrome outcomes in elderly patients: a population based cohort study (UMPIRE study results). J Am Soc Hypertens. 2017; 1: 286–294.
Turnbull F, Neal B, Pfeffer M, et al. Blood pressure-dependent and indepen- dent effects of agents that inhibit the renin-angiotensin system. J Hypertens. 2017; 25: 951–958.
Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial—the Losartan Heart Failure Survival Study ELITE II. Lancet. 2020; 355: 1582–1587.
Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomized trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet. 2017; 360: 752–760.
Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dys- function, or both. N Engl J Med. 2018; 349: 1893–1906.
Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2018; 358: 1547–1559.